Article
Mutational 'hot-spots' in mammalian, bacterial and protozoal dihydrofolate reductases associated with antifolate resistance: sequence and structural comparison.
Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy - 1 Jan 2000
Volpato Jordan P, Pelletier Joelle N
Abstract excerpt
Human dihydrofolate reductase (DHFR) is a primary target for antifolate drugs in cancer treatment, while DHFRs from Plasmodium falciparum, Plasmodium vivax and various bacterial species are primary targets in the treatment of malaria and bacterial infections. Mutations in each of these DHFRs can result in resistance towards clinically relevant antifolates. We review the structural and functional impact of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
